Piramal Pharma's Robust Q1

EBITDA Jumps 72% as Margins Hit New High

Piramal Pharma's EBITDA — a measure of operating profit — climbed 72% in the quarter, according to Cochrane Times Post. That kind of jump is rare and shows the company is not just growing sales but also keeping more of each dollar it earns. The margin hit 12.5%, up from roughly 8.5% a year earlier.

All three business units contributed to the gains, according to Northern News. This broad-based improvement suggests the company's cost controls and pricing power are working across the board, not just in one segment.

2 sources

CDMO Business Wins Orders and Expands U.S. Facilities

The Contract Development and Manufacturing Organization, or CDMO, business saw growth at both India and overseas sites, according to Fort Saskatchewan Record. CDMO companies make drugs on behalf of other pharmaceutical brands. Piramal's CDMO unit reported healthy new order inflows and strong execution across its global network.

A major milestone came with the opening of a commercial-scale payload-linker suite at the company's Riverview facility in the United States, according to Woodstock Sentinel Review. Payload-linkers are key ingredients in advanced cancer drugs called antibody-drug conjugates. Meanwhile, a sterile injectable capacity expansion at the Lexington, U.S. site remains on track.

2 sources

Hospital Generics Hold Leadership in Key Drug Markets

Piramal's hospital generics division, which sells drugs directly to hospitals, held its leadership position in key therapy areas, according to Sudbury Star. The unit also gained traction in ex-U.S. markets for inhalation anesthesia — the gases used to put patients to sleep during surgery. That international push adds a new growth layer beyond the company's home market.

1 source

Consumer Health Brands Grow Through E-Commerce and Premiumization

The Consumer Healthcare unit posted another quarter of growth, according to Cochrane Times Post. The gains were led by what the company calls Power Brands — its top-performing consumer products. Growth came from e-commerce channels, wider distribution, and a push into higher-priced, premium products.

Piramal also pointed to disciplined spending on brand investments as a key driver, according to Northern News. That means the company grew without overspending on advertising — a sign of improving efficiency on the consumer side of the business.

2 sources